Peripheral neuropathy in HIV infection

Beckonja, 2002, Use of anticonvulsants for treatment of neuropathic pain, Neurology, 59, S14, 10.1212/WNL.59.5_suppl_2.S14 Blum, 1996, Low dose zalcitabine‐related toxic neuropathy, Neurology, 46, 999, 10.1212/WNL.46.4.999 Brew, 2003, Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy, AIDS, 17, 1094, 10.1097/00002030-200305020-00024 Caniatti, 1996, Cryoglobinemic neuropathy related to hepatitis C virus infection. Clinical, laboratory and neurophysiological study, J Peripher Nerv Syst, 1, 131 Childs, 1999, Plasma viral load and CD4 lymphocytes predict HIV‐associated dementia and sensory neuropathy, Neurology, 52, 607, 10.1212/WNL.52.3.607 Christensen, 2004, Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high dose coenzyme Q treatment: a randomized, double‐blind, placebo‐controlled pilot study, Clin Infect Dis, 39, 1371, 10.1086/424881 Cornblath, 1987, Inflammatory demyelinating peripheral neuropathies associated with human T‐cell lymphotropic virus type III infection, Ann Neurol, 21, 32, 10.1002/ana.410210107 Dalakas, 1990, Mitochondrial myopathy caused by long‐term zidovudine therapy, N Engl J Med, 322, 1098, 10.1056/NEJM199004193221602 Dalakas, 2001, Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′ dideoxycytidine (ddC), Lab Invest, 81, 1537, 10.1038/labinvest.3780367 Estanislao, 2004, HIV neuromuscular disease and mitochondrial function, Mitochondrion, 4, 131, 10.1016/j.mito.2004.06.007 Evans, 2003, Randomized trial of cognitive behavior therapy versus supportive psychotherapy for HIV‐related peripheral neuropathic pain, Psychosomatics, 44, 44, 10.1176/appi.psy.44.1.44 Evans, 2003, Assessing negative thoughts in response to pain among people with HIV, Pain, 105, 239, 10.1016/S0304-3959(03)00220-3 Griffin, 1998 Gulick, 1998, Combination therapy for patients with HIV‐1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents, AIDS, 12, S17 Hahn, 2004, A placebo‐controlled trial of gabapentin for painful HIV‐associated sensory neuropathies, J Neurol, 251, 1260, 10.1007/s00415-004-0529-6 Hart, 2004, Acetyl‐l‐carnitine: a pathogenesis based treatment for HIV‐associated antiretroviral toxic neuropathy, AIDS, 18, 1549, 10.1097/01.aids.0000131354.14408.fb Keswani, 2002, HIV‐associated sensory neuropathies, AIDS, 16, 2105, 10.1097/00002030-200211080-00002 Keswani, 2003, Schwann cell chemokine receptors mediate HIV‐1 gp120 toxicity to sensory neurons, Ann Neurol, 54, 287, 10.1002/ana.10645 Keswani, 2004, Erythropoietin is neuroprotective in models of HIV sensory neuropathy, Neurosci Lett, 371, 102, 10.1016/j.neulet.2004.08.080 Lanska, 1988, Syphilitic polyradiculopathy in an HIV‐positive man, Neurology, 38, 1297, 10.1212/WNL.38.8.1297 Leger, 1992, Lymphoma‐induced polyradiculopathy in AIDS: two cases, J Neurol, 239, 132, 10.1007/BF00833911 Lewis, 1995, Mitochondrial toxicity of antiviral drugs, Nat Med, 1, 417, 10.1038/nm0595-417 Lichtenstein, 2005, Modification of the incidence of drug‐associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort, Clin Infect Dis, 40, 148, 10.1086/426076 Lopez, 2004, Risk modifiers for peripheral sensory neuropathy in HIV infection, Eur J Neurol, 11, 97, 10.1046/j.1351-5101.2003.00713.x Manji, 2000, Neuropathy in HIV infection, Curr Opin Neurol, 13, 589, 10.1097/00019052-200010000-00014 Marra, 1998, Screening for distal sensory peripheral neuropathy in HIV‐infected persons in research and clinical settings, Neurology, 51, 1678, 10.1212/WNL.51.6.1678 Martin, 2000, Antiretroviral therapy may improve sensory function in HIV‐infected patients: a pilot study, Neurology, 54, 2120, 10.1212/WNL.54.11.2120 McArthur, 2003, Emerging neurological complications of HIV McArthur, 2000, A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS clinical trial group team 291, Neurology, 54, 1080, 10.1212/WNL.54.5.1080 Moore, 2000, Incidence of neuropathy in HIV‐infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea, AIDS, 14, 273, 10.1097/00002030-200002180-00009 Moyle, 1998, Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence, and management, Drug Safety, 19, 481, 10.2165/00002018-199819060-00005 Paice, 2000, Topical capsaicin in the management of HIV‐associated peripheral neuropathy, J Pain Symptom Manage, 19, 45, 10.1016/S0885-3924(99)00139-6 Pardo, 2001, HIV neuropathy: insights in the pathology of HIV peripheral nerve disease, J Periph Nervous Syst, 1, 21, 10.1046/j.1529-8027.2001.006001021.x Savasta, 2004, HIV associated transmission risks in older adults: an integrative review of the literature, J Assoc Nurses AIDS Care, 15, 50, 10.1177/1055329003252051 Schifitto, 1997, HIV related vasculitic mononeuropathy multiplex: a role for IVIg?, J Neuro Neurosurg Psych, 63, 255, 10.1136/jnnp.63.2.255a Schifitto, 2002, Incidence of and risk factors for HIV‐associated distal symmetrical sensory polyneuropathy, Neurology, 58, 1764, 10.1212/WNL.58.12.1764 Schifitto, 2005, Markers of immune activation and viral load in HIV‐associated sensory neuropathy, Neurology, 64, 842, 10.1212/01.WNL.0000152981.32057.BB Simpson, 1992, Peripheral neuropathies associated with human immunodeficiency virus infection, Periph Neuropathies: New Concepts Treat, 685 Simpson, 1995, Nucleoside analogue‐associated peripheral neuropathy in human immunodeficiency virus infection, J AIDS, 9, 153 Simpson, 2000, A placebo‐controlled study of lamotrigine in the treatment of painful HIV‐associated neuropathy, Neurology, 54, 2115, 10.1212/WNL.54.11.2115 Simpson, 2002, Severity of HIV‐associated neuropathy is associated with plasma HIV‐1 RNA levels, AIDS, 16, 407, 10.1097/00002030-200202150-00012 Simpson, 2003, Lamotrigine for HIV‐associated painful sensory neuropathies: a placebo controlled trial, Neurology, 60, 1508, 10.1212/01.WNL.0000063304.88470.D9 Simpson, 2004, A single application of high concentration trans‐capsaicin leads to 12 weeks of pain relief in HIV DSP: results of an open label trial Simpson, 2005, HIV neuropathy natural history cohort study: clinical and laboratory features and risk factors for progression Tyor, 1995, Unifying hypothesis for the pathogenesis of HIV‐associated dementia complex, vacuolar myelopathy, and sensory neuropathy, J Acquir Immune Defic Syndr Hum Retrovir, 9, 379, 10.1097/00042560-199508000-00008 Verma, 2004, Controlling neuropathic pain in HIV, Curr Infec Dis Rep, 6, 237, 10.1007/s11908-004-0014-5 Wesselingh, 1994, Cytokine dysregulation in HIV‐associated neurological disease, Adv Neuroimmunol, 4, 199, 10.1016/S0960-5428(06)80258-5 1990, Cancer Pain Relief and Palliative Care 1996 Wulff, 1998, HIV‐associated neuropathy: recent advances in management, HIV Adv Res Ther, 8, 23 Yarchoan, 1990, Long‐term toxicity/activity profile of 2′,3′‐dideoxyinosine in AIDS or AIDS‐related complex, Lancet, 336, 526, 10.1016/0140-6736(90)92085-V Yoshioka, 1994, Expression of HIV‐1 and interleukin‐6 in lumbosacral dorsal root ganglia of patients with AIDS, Neurology, 44, 1120, 10.1212/WNL.44.6.1120 Leger, 1989, The spectrum of polyneuropathies in patients infected with HIV, J Neurol Neurosurg Psych, 52, 1369, 10.1136/jnnp.52.12.1369